Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) shares in Millions, $ in Millions		Total	Common stock	Additional paid-in capital	Accumulated deficit	Accumulated other comprehensive loss
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Impact due to adoption of ASU 2018-02	[1]				$ 3.2	$ (3.2)
Beginning balance (in shares) at Dec. 31, 2018			141.7
Beginning balance at Dec. 31, 2018		$ 1,191.7	$ 1.4	$ 2,325.0	(761.5)	(373.2)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)		(45.1)			(45.1)
Foreign currency translation adjustment		(12.1)				(12.1)
Pension and other postretirement benefits adjustment		0.1
Derivative financial instruments, net of tax		(28.6)				(28.6)
Common stock issued for the Nexeo acquisition (in shares)	[2]		27.9
Common stock issued for the Nexeo acquisition	[2]	649.3	$ 0.3	649.0
Shares cancelled (in shares)			(1.5)
Shares cancelled		(35.5)		(35.5)
Restricted stock units vested (in shares)			0.4
Tax withholdings related to net share settlements of stock-based compensation awards (in shares)			(0.2)
Tax withholdings related to net share settlements of stock-based compensation awards		(2.8)		(2.8)
Stock option exercises (in shares)			0.3
Stock option exercises		5.7		5.7
Employee stock purchase plan		0.6		0.6
Stock-based compensation		21.7		21.7
Ending balance (in shares) at Sep. 30, 2019			168.6
Ending balance at Sep. 30, 2019		1,745.0	$ 1.7	2,963.7	(803.4)	(417.0)
Beginning balance (in shares) at Jun. 30, 2019			168.6
Beginning balance at Jun. 30, 2019		1,774.5	$ 1.7	2,959.4	(805.9)	(380.7)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)		2.5			2.5
Foreign currency translation adjustment		(31.9)				(31.9)
Derivative financial instruments, net of tax		(4.4)				(4.4)
Restricted stock units vested (in shares)			0.1
Tax withholdings related to net share settlements of stock-based compensation awards (in shares)			(0.1)
Tax withholdings related to net share settlements of stock-based compensation awards		0.0		0.0
Stock-based compensation		4.4		4.4
Other		(0.1)
Ending balance (in shares) at Sep. 30, 2019			168.6
Ending balance at Sep. 30, 2019		$ 1,745.0	$ 1.7	2,963.7	(803.4)	(417.0)
Beginning balance (in shares) at Dec. 31, 2019		168.7	168.7
Beginning balance at Dec. 31, 2019		$ 1,732.8	$ 1.7	2,968.9	(858.5)	(379.3)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)		86.6			86.6
Foreign currency translation adjustment		(60.1)				(60.1)
Pension and other postretirement benefits adjustment		0.1				0.1
Derivative financial instruments, net of tax		(18.8)				(18.8)
Restricted stock units vested (in shares)			0.4
Restricted stock units vested		0.0
Tax withholdings related to net share settlements of stock-based compensation awards (in shares)			(0.1)
Tax withholdings related to net share settlements of stock-based compensation awards		(2.0)		(2.0)
Stock option exercises (in shares)			0.1
Stock option exercises		0.7		0.7
Employee stock purchase plan		0.7
Stock-based compensation		10.9		10.9
Other		$ 0.1
Ending balance (in shares) at Sep. 30, 2020		169.1	169.1
Ending balance at Sep. 30, 2020		$ 1,751.0	$ 1.7	2,979.3	(771.9)	(458.1)
Beginning balance (in shares) at Jun. 30, 2020			169.0
Beginning balance at Jun. 30, 2020		1,703.2	$ 1.7	2,977.3	(800.8)	(475.0)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)		28.9			28.9
Foreign currency translation adjustment		14.3				14.3
Derivative financial instruments, net of tax		2.6				2.6
Restricted stock units vested (in shares)			0.1
Tax withholdings related to net share settlements of stock-based compensation awards		(0.6)		(0.6)
Stock-based compensation		$ 2.6		2.6
Ending balance (in shares) at Sep. 30, 2020		169.1	169.1
Ending balance at Sep. 30, 2020		$ 1,751.0	$ 1.7	$ 2,979.3	$ (771.9)	$ (458.1)

[1] Adjusted due to the adoption of ASU 2018-02 “Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income” on January 1, 2019.

[2] Refer to “Note 3: Business combinations” for more information.